MedPath

The NOR-COR Study for Coronary Prevention

Completed
Conditions
Secondary Coronary Prevention
Interventions
Other: no intervention
Registration Number
NCT02309255
Lead Sponsor
Vestre Viken Hospital Trust
Brief Summary

The NOR-COR study is a cross-sectional, observational study designed to explore a large number of cardiovascular, inflammatory, genetic, behavioral, and psychosocial factors (including anxiety, depression, quality of life) in 1369 patients with established coronary heart disease (CHD) hospitalized in the Sections for Cardiology at the hospitals in Drammen (n=722) and Vestfold (n=647). Study data from an extensive questionnaire, clinical and laboratory data, and sputum/saliva for genetic analyses will be collected.

The main overall aim of the NOR-COR study is to develop new strategies to improve secondary prevention for underserved high risk patient-groups with CHD. The first study phase aims to collect information necessary to develop empirically based future secondary coronary prevention interventions. In a genetic sub-project markers associated with CHD and personality type will be explored.

The study will evaluate current secondary preventive programs and explore the mechanisms that link behavioral, psychosocial, inflammatory, and genetic factors to poor prognosis. The study will in short term provide new knowledge potentially useful for increasing participation in current cardiac rehabilitation/secondary preventive programs. For a longer perspective these associations may be useful for design of new intervention programs to selected high risk patient groups whom may be in need of programs with different content and/or of longer duration than those currently being applied.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
975
Inclusion Criteria

Not provided

Exclusion Criteria
  • Cognitive impairment that would invalidate assessment including all patients living at nursing home and psychosis.
  • Short life expectancy (i.e. <1 year) due to terminal heart (NYHA class 4), lung (chronic obstructive pulmonary disease GOLD 4)-, liver- or kidney disease (chronic kidney disease stage 5), malignant disease, or other reason.
  • Not able to understand and write the Norwegian language or refuse to give written informed consent to study participation.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
coronary heart disease patientsno intervention-
Primary Outcome Measures
NameTimeMethod
Cardiovascular risk factors, lifestyle, and drug adherenceWithin 2 years after study inclusion
Secondary Outcome Measures
NameTimeMethod
Readmission with a coronary event, acute myocardial infarctrion and cardiovascular mortalityWithin 5 years after study inclusion

Trial Locations

Locations (1)

Vestre Viken HF, Drammen Hospital and The Hospital of Vestfold

🇳🇴

Drammen and Tønsberg, Buskerud and Vestfold, Norway

© Copyright 2025. All Rights Reserved by MedPath